Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez-Casero, M. V.
Right arrow Articles by Kornberg, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez-Casero, M. V.
Right arrow Articles by Kornberg, A. J.
Related Collections
Right arrow Guillain-Barre syndrome
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow All Pediatric
NEUROLOGY 2005;64:1786-1788
© 2005 American Academy of Neurology


Brief Communications

Subacute inflammatory demyelinating polyneuropathy in children

M. Victoria Rodriguez-Casero, MD, Lloyd K. Shield, MBBS (Hons), FRACP and Andrew J. Kornberg, MBBS (Hons), FRACP

From the Department of Neurology, Royal Children’s Hospital, Parkville, Victoria, Australia.

Address correspondence and reprint requests to Dr Kornberg, Department of Neurology, Royal Children’s Hospital, Flemington Road, Parkville, Victoria, Australia 3052; e-mail: andrew.kornberg{at}rch.org.au

Reported are five children with subacute demyelinating polyneuropathy. All patients had a monophasic disease, progressing over 4 to 8 weeks and characterized by predominantly motor features, areflexia, minimal or no cranial nerve abnormalities, no autonomic or respiratory involvement, elevated CSF protein, electrophysiologic evidence of demyelination, and good response to corticosteroids. A benign course with full recovery was the rule.


Supported by an educational grant from CSL Bioplasma Limited, Victoria, Australia (M.V.R.-C.).

Received August 10, 2004. Accepted in final form February 3, 2005.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.